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Abstract 
 
Background: Cardiac Troponin I (cTnI) is frequently measured in patients 
presenting with symptomatic Atrial Fibrillation (AF). The significance of 
elevated cTnI levels in this patient cohort is unclear. We investigated the 
value of cTnI elevation in this setting and whether it is predictive for significant 
Coronary Artery Disease (sCAD). 
 
Methods: We conducted a retrospective, single-center, case-control study of 
231 patients who presented with symptomatic AF to The Prince Charles 
Hospital emergency department, Brisbane, Australia between 2006 and 2014. 
Patients who underwent serial cTnI testing and assessment for CAD were 
included. Clinical variables that are known to predict CAD and could 
potentially predict cTnI elevation were collected. Binary logistic regression 
was performed to identify predictors of sCAD and cTnI elevation.  
 
Results: Cardiac Troponin I elevation above standard cut off was not 
predictive for sCAD after adjustment for other predictors (OR 1.62, 95% CI 
0.79 – 3.32. p= 0.19). However, the highest cTnI concentration value (cTnI 
peak) was predictive for sCAD (OR 2.02, 95% CI 1.02 -3.97, p=0.04).   
Dyspnea on presentation (OR 4.52, 95% CI 1.87 – 10.91, p=0.001), known 
coronary artery disease (OR 3.44, 95% CI 1.42 – 8.32, p=0.006), and ST 
depression on the initial electrocardiogram (OR 2.57, 95% CI 1.11 – 5.97, 
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p=0.028) predicted sCAD in our cohort, while heart rate on initial presentation 
was inversely correlated with sCAD (OR 0.99, 95% CI 0.971 – 1.00, p=0.034).  
 
Conclusion: Troponin elevation is common in patients presenting to hospital 
with acute symptomatic AF and it is not a reliable indicator for underlying 
sCAD in this patient cohort. However, cTnI peak was a predictor of significant 
coronary artery disease.  
 
 
1-Introduction 
 
AF is the most common cardiac arrhythmia requiring hospital care with a 
prevalence that rises with age. It has an estimated prevalence of 
approximately 4% among patients 60 years or older and approximately 9% 
among patients 80 years or older [1]. AF is frequently associated with 
cardiovascular diseases such as hypertension (HTN), valvular and congenital 
heart disease, cardiomyopathies and coronary artery disease [1-3].  
 
Patients with AF can present with symptoms suggestive of myocardial 
ischemia such as chest pain and dyspnea. Their electrocardiogram (ECG) 
often demonstrates ST depression in association with rapid ventricular rate, 
which has been termed a stress test equivalent [4, 5]. Hence, it is not 
surprising that looking for CAD or ruling out an Acute Coronary Syndrome 
(ACS) is a significant part of the clinical burden of managing this patient 
cohort [5, 6].  
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Cardiac troponins, including cTnI, are the most sensitive and specific 
biomarkers of myocardial injury, whereby troponin elevation is part of the 
universal definition of myocardial infarction [7, 8]. Cardiac troponins can be 
elevated in a wide variety of clinical settings including AF, even in the 
absence of sCAD [9-14]. This has been attributed to myocardial oxygen 
supply and demand mismatch (Type two myocardial infarction) [15].  
However, troponin elevation in these settings translates into poorer prognosis 
and increased mortality [16-19]. 
 
Although major society guidelines do not include troponin measurement as a 
part of the diagnostic workup for AF, approximately 86% of patients 
presenting with AF will have their cardiac biomarkers tested with 
approximately 4% of patients with elevated troponin diagnosed with ACS [20-
22]. The challenge for physicians treating patients presenting with 
symptomatic AF and an elevated troponin concentration is to astutely judge 
which patient should be aggressively investigated and treated for ACS caused 
by significant CAD. 
 
The aim of this study is to determine the reliability of cardiac troponin 
elevation in diagnosing significant coronary artery stenosis in patients 
presenting with symptomatic atrial fibrillation. We also aim to investigate other 
possible predictors of sCAD and cardiac troponin elevation in these patients. 
 
 
2- Methods 
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2.1. Patients Selection 
We conducted a retrospective case-control study of patients who presented to 
the emergency department of The Prince Charles Hospital, Brisbane, 
Australia between January 2006 and January 2014 with a primary diagnosis 
of AF. This hospital is a 630-bed quaternary, university-affiliated teaching 
center. 
 
Patients were included if they were ≥ 18 years of age, presented with cardiac 
symptoms (chest pain, dyspnea or palpitations), had serial cardiac troponin 
measurements taken, with an admission twelve-lead ECG result showing AF. 
Patients required an invasive or non-invasive coronary artery assessment 
during or within six months of the index hospital admission to be included.  
 
We excluded patients with ST-Elevation Myocardial Infarction (STEMI), AF 
due to concomitant predisposing illness or asymptomatic AF. Patients with 
prior cardiac surgery including coronary bypass surgery, underlying complex 
congenital heart disease, or valvular AF were also excluded.  
 
The sample was identified using the coding system utilized for hospital 
reimbursement.  During the study period, 3548 patients presented with AF. Of 
these, 2627 did not satisfy the inclusion criteria on review of the patient’s 
imaging results, laboratory data and discharge summaries. After medical 
charts review, a further 690 patients were excluded due to the absence of 
cardiac symptoms, and/or no coronary artery testing on or within six months 
from the index hospital admission. Subsequently, 231 were included in the 
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final study set. Of these 231 patients, 107 had cTnI elevation, and 124 had 
negative cTnI on serial measurements (Fig. 1). 
 
2.2. Data collection:  
 
Data was collected through a careful review of patient records using a 
standardized data collection template. We recorded patient demographics, 
their presenting symptoms, risk factors for CAD and the CHADS2 stroke risk 
model scores. Heart rate and degree of ST segment depression were 
measured from a 12 lead ECG.  Left ventricular ejection fraction (EF) and 
presence of valvular AF were determined from echocardiography results. 
Laboratory data including two serial troponin measurements on admission 
and within six to nine hours from the initial measurement were collected.  We 
examined the results of coronary angiography or non-invasive cardiac 
imaging to determine the presence of sCAD. 
2.3. Definitions: 
Significant CAD was defined as one or more of the following coronary artery 
stenosis: 
1- ≥ 70% diameter 
2- 50% to 70% diameter stenosis with Fractional Flow Reserve (FFR) 
confirmed hemodynamic significance 
3- 50% to 70% Left Main Coronary Artery (LMCA) disease confirmed by 
Intravascular Ultrasound (IVUS) to be significant.  
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This definition is in keeping with The American College of Cardiology 
Foundation/American Heart Association Task Force on Practice Guidelines 
and the Society for Cardiovascular Angiography and Interventions for 
percutaneous coronary intervention (ACCF/AHA/SCAI) 2011 guidelines [23]. 
Non-invasive coronary artery disease test results were interpreted by a 
cardiologist or a radiologist specialised in cardiac imaging. Any reported 
positive test with a high probability of CAD was followed by gold standard 
invasive coronary angiography . 
AF was classified into the categories of first diagnosed AF, paroxysmal AF, 
persistent AF, long-standing persistent AF and permanent AF.  These 
categories are in accordance with the 2014 American College of Cardiology 
/American Heart Association/ Heart Rhythm Society (AHA/ACC/HRS) task 
force on practice guidelines, and the 2010 European Society of Cardiology 
(ESC) Guidelines [24, 25]. 
Known CAD was defined as prior angiography showing non-significant 
disease or previous percutaneous coronary intervention. ST-segment 
depression was defined as ≥1.0-mm horizontal or downsloping depression 
0.08 second after the J-point on a 12-lead electrocardiogram[10] 
 
2.4. Troponin assay: 
cTnI testing was performed on Beckman Coulter AccuTnI analyzers 
(Beckman Coulter, Brea, CA, USA) with 99th percentile cut-off value of 0.040 
μg/L. 
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2.5. Statistical analysis: 
 
Descriptive statistics were reported as mean (standard deviation (SD)), 
median (interquartile range (IQR)) or frequency (percent). Univariable 
analyses were performed to assess the relationship between potential 
predictors against sCAD and cTnI elevation. Chi-square tests were used for 
categorical predictors (Fisher’s exact test was used when the assumptions of 
the chi-square test were not met) and one-way ANOVAs for parametric 
continuous variables (Mann-Whitney U test was used in place of ANOVA for 
non-parametric data). Those with a p-value less than 0.15 were considered 
for modeling via binary logistic regression. Backwards elimination was used to 
obtain the final model.  
 
ROC curve analyses were performed, and Youden Indices calculated to 
determine a suitable cut-off point of cTnI peak to predict sCAD. Youden Index 
was defined as the sensitivity + specificity – 1. This ROC analysis was 
repeated stratified by model covariates. Data analyses were performed using 
IBM SPSS Statistics for Windows (2013, IBM Corp., Armonk, NY., USA). 
 
3-Results 
 
The mean age was 66.1 (SD 12.7) years with 49.4% being females (114). The 
mean BMI of the participants was 30.6 (SD 6.6) kg/m2. 100 patients 
underwent Invasive coronary angiography (43%) of patients, including 46 with 
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negative cTnI and 54 with elevated cTnI. CT Coronary Angiography (CTCA), 
myocardial perfusion scan, exercise stress test, stress echocardiography 
were used in 15%, 39%, 7% and 4% of patients respectively. 
 
One hundred and twenty-four patients (54%) had negative cTnI, and 107 
(46%) had elevated cTnI. A total of 42 patients had sCAD requiring 
revascularization (18.2%), of which 24 patients had elevated cTnI (57%) and 
18 had negative cTnI (43%). In patients with elevated cTnI, the mean cTnI 
peak was 1.14 (range 0.041 – 47), compared to 0.02 (range 0.01 - 0.04) in the 
cTnI negative group. Troponin I elevation above the 99th percentile cut-off 
value used to diagnose ACS had a sensitivity of 57% and specificity of 56% 
for detection of sCAD. 
 
3.1. Modeling troponin elevation 
 
The relationships between troponin elevation and possible predictors are 
detailed in Table 1. 
 
An initial model was run incorporating age, BMI, heart rate, gender, DM, 
CHADS2, dyslipidemia and ST depression to predict cTnI elevation. We had 
concerns given CHADS2 score is a composite measure, which includes 
diabetes mellitus and age along with other stroke risk measures. Therefore, 
the collinearity between these variables was investigated, but showed no 
concerns. We also carefully considered that these factors were one of five 
measures used in the CHADS2 composite score and were still important to 
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specify their individual effects in modeling cTnI elevation given that their 
effects may be diluted by the other CHADS2 measures. After removal of 
predictors that did not contribute to the model, the following final model 
resulted (Table 2).  
 
Heart rate and ST depression were significant predictors of cTnI elevation. 
The model shows that for every unit increase in heart rate, the odds of 
positive cTnI (>0.04) were 1.02 (95% CI: 1.01 – 1.03). Those with ST 
depression had 2.24 increased odds of having a positive cTnI measurement 
compared to those who did not.  
 
3.2. Modeling sCAD 
 
Similarly, patient characteristics and clinical variables against the outcome of 
sCAD were explored (Table 3). 
 
Two initial models were set up; one with cTnI elevation as the main predictor 
of interest (model 1) and another with cTnI peak as the main predictor of 
interest (model 2). Each of these models were initially set up with heart rate, 
EF, creatinine, TSH, gender, CCF, known CAD, ST depression, dyspnea, 
palpitation and type of AF as predictors of sCAD outcome. The final adjusted 
model resulted after removal of non-significant covariates. Table 4 outlines 
the associations between troponin measures before and after final adjustment 
for other significant predictors.  
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Troponin elevation above the 99th percentile cut-off did not predict significant 
coronary artery disease in patients presenting with atrial fibrillation (OR 1.62, 
95% CI 0.79 – 3.32. p= 0.19).  However, the highest cTnI concentration 
measured (cTnI peak) was a strong predictor of sCAD, after adjustment for 
heart rate, known CAD, ST depression, and dyspnea (adjusted OR 2.02, 95% 
CI 1.02 -3.97, p=0.04).  
 
Other clinical predictors of sCAD apart from cTnI peak (model 2) included 
dyspnea (OR 4.52, 95% CI 1.87 – 10.91, p=0.001); ST depression on the 
electrocardiogram (OR 2.57, 95% CI 1.11 – 5.97, p=0.028) and known history 
of coronary artery disease (OR 3.44, 95% CI 1.42 – 8.32, p=0.006).  Rapid 
heart rate was inversely correlated with subsequent finding of sCAD (OR 
0.99, 95% CI 0.97 – 1.00, p=0.034).  
  
3.3. Youden Index for cut-off point for cTnI peak as a predictor of CAD 
 
To determine if a suitable threshold level of cTnI peak could be used to 
classify sCAD, ROC curve analysis for classification of sCAD from cTnI peak 
was performed (Fig. 2).  
Although statistically significant (p=0.001), the area under the curve value of 
0.67 (95% CI 0.58 – 0.76) indicates that cTnI peak as a diagnostic test is 
inadequate in discriminating between those with sCAD and those without 
sCAD and no sensible cut-off point for cTnI peak was able to be determined.  
The Youden index was 0.25 with a corresponding cTnI peak cut-off of 0.1.  
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This analysis was also performed stratified by the covariates of known CAD, 
ST depression and dyspnea but did not yield a large improvement in area 
under the curve. 
 
4- Discussion  
When a patient presents to the hospital with symptomatic AF, ST depression 
on the ECG or a troponin elevation, the treating clinician needs to decide on 
how aggressively to investigate for underlying CAD.   Recognizing patients 
with significant underlying CAD can improve outcomes with appropriate 
medical therapy or revascularisation [26, 27]. Accurately excluding those 
without significant CAD would also mitigate the increased bleeding risk 
associated with the unnecessary use of antiplatelet therapy added to the 
standard anticoagulation therapy for stroke prevention in AF. Additionally, a 
subset of patients who would benefit from class 1C antiarrhythmic therapy 
would need exclusion of sCAD prior to commencing such therapy for AF [28, 
29]. 
The reported prevalence of sCAD in patients with AF varies widely from 22% 
to 49% due to heterogeneous patient cohorts and variable diagnostic criteria 
for defining sCAD [4, 30-36]. It was slightly lower in our patient cohort (18.2%) 
perhaps due to strict selection of patients presenting primarily with 
symptomatic AF and applying the ACCF/AHA/SCAI guideline definitions for 
significant coronary disease. Although CAD and AF share common risk 
factors including age, hypertension, obesity, and Diabetes Mellitus [37], our 
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analysis showed that these risk factors did not predict sCAD in patients 
presenting with symptomatic AF. 
There is now increasing awareness that troponin elevation in patients 
presenting with symptomatic AF may not need to be managed as an acute 
coronary syndrome.  Our data showed that cTnI elevation above the 99th 
percentile cut value used to diagnose ACS did not predict sCAD with a 
sensitivity of 57% and specificity of 56%. Nonetheless, the peak troponin 
value was a strong predictor of sCAD.  Higher troponin concentrations are 
more specific to myocardial infarction due to significant CAD with higher 
troponin values representing larger infarct size [15]. In this study, all patients 
with a cTnI value exceeding 2.1 μg/L had CAD requiring revascularization. 
However, the study was not able to define a reliable cut-off to accurately 
diagnose sCAD. The addition of a relative or absolute change in cTnI 
concentration between serial readings might improve the diagnostic accuracy 
in this setting [38]. 
 
ST segment depression has been thought of as a “positive stress test 
equivalent” in patients presenting with AF and rapid ventricular response. As a 
result, the value of ST segment depression in diagnosing sCAD has been 
explored in multiple studies, but the results are conflicting [4, 33, 36]. In our 
patient cohort, ST depression was a significant covariate in the prediction of 
sCAD, which supports the theory that ST depression in those patients reflects 
sub-endocardial ischemia. Interestingly, the presenting complaint of dyspnea 
was found to have a strong relationship with the presence of CAD in 
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symptomatic AF patients. The mechanism of dyspnea in AF is poorly 
understood and it has been attributed to low cardiac output as a consequence 
of impaired diastolic left ventricular filling and increased left-sided intra-cardiac 
pressure due to diastolic dysfunction[39, 40]. However, hemodynamic studies 
in AF have previously shown normal or even low intra-cardiac pressures[41]. 
The exact mechanism of dyspnea in these patients requires future dedicated 
hemodynamic study.  
In contrast to a previous study, where heart rate, left ventricular function, the 
presence of angina pectoris, serum creatinine and hemoglobin were 
associated with troponin rise in atrial fibrillation patients [14], heart rate on 
presentation, CHADS2 score, and presence of ST depression on admission 
ECG were the significant predictors in our study. In the setting of AF with fast 
ventricular response, cTnI elevation and ST depression may be due to oxygen 
demand-supply mismatch caused by the increased metabolic requirements of 
the fast beating ventricles coupled with impaired subendocardial blood flow 
due to the shortening of diastole[12]. 
Our study has several strengths.  Namely, this is one of very few studies that 
looked at predictors of severe coronary disease in AF patients using cardiac 
biomarkers. We excluded patients with prior cardiac surgery, complex 
congenital heart disease and AF due to acute reversible causes. Unlike other 
studies of similar nature, we did not exclude patients with a diagnosis of ACS 
and a serial troponin measurement was an essential inclusion criterion [14, 
26, 27].  
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This was a retrospective case-control study that carries all the inherent 
limitation of retrospective research. We depended on a hospital record coding 
system to identify our patient cohort, and we only included patients who had 
been investigated for coronary artery disease either by invasive coronary 
angiography or non-invasive cardiac testing. This design may have led to 
selection and information biases. However, we endeavored to obtain good 
quality data through the use of well-defined end points (e.g. cTnI 
measurement, ST depression and cardiac catheterization results) that are 
less subject to bias.  Our sample size (n=231) is similar to previously reported 
studies on this subject[14]. Still, our sample size was still inadequate to 
identify a precise cTnI peak cut-off value that could accurately predict 
significant underlying CAD. 
 
Invasive coronary angiography was performed in only 43% of patients whilst 
non-invasive modalities including functional tests and CTCA were used in 
most of our patients.  All forms of non-invasive cardiac testing for significant 
CAD in patients with AF are plagued by a lower specificity [4, 42]. However 
the impact of potential false positive non-invasive test results was minimal in 
our study, as only 2 patients with positive non-invasive testing did not proceed 
to coronary angiography. Due to the retrospective nature of this study, we 
were also unable to control for the types of cardiac testing used in the groups 
with and without cTnI elevation.   
 
A prospective study where all patients presenting with symptomatic AF 
subsequently undergo coronary angiography would give a clearer answer as 
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to whether patient risk factors, symptoms, troponin measurement or ST 
depression on ECG are accurate predictors for significant CAD in this cohort.  
This type of study may be difficult to perform ethically because many patients 
would undergo invasive angiography unnecessarily. Perhaps research needs 
to move beyond the assessment of sensitivity, specificity and accuracy of a 
given test to predict significant CAD in this patient group.  Studies are needed 
to investigate whether looking for CAD in patients with AF affects hard 
cardiovascular outcomes. 
5- Conclusion: 
Troponin elevation per se is common in patients presenting to hospital with 
symptomatic AF and it is not a reliable indicator for underlying significant 
CAD. However, higher cTnI concentration on serial measurements is strongly 
associated with underlying significant coronary artery disease. Dyspnea, 
previous history of coronary disease, lower heart rate, and ST segment 
depression were additional predictors of significant CAD. These findings may 
help guide the decision on how aggressively to investigate for CAD in this 
group of patients. 
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Figure 1: Flow chart for final cohort 
Figure 2. ROC curve for cTnI peak for prediction of sCAD  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Flow chart for final cohort 
 
 
 
 
 
 
 
3548 were coded 
as  AF between 
Jan 2006 and Jan 
2014 
•2627 were excluded due to the absence of 
serial cTnI, prior cardiac surgery, underlying 
acute systemic illness precipitating AF, 
Valvular AF, underlying complex congenital 
heart disease or discharge diagnosis of 
different tachyarrhythmia rather than AF.  
921 for chart 
review 
•690 excluded due to absence of 
cardiac symptoms and no invasive or 
non-invasive coronary artery test on 
or within 6 months from the index 
hospital admission 
231 included in 
final analysis  
•107 troponin 
positive 
•124 troponin 
negative 
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Figure 2. ROC curve for cTnI peak for prediction of sCAD 
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Table 1. Relationship of patient characteristics and clinical variables against cTnI elevation 
Variable Categories cTnI negative 
(n=124) 
cTnI positive 
(n=107) 
p-value 
Gender Female 55 (48.2%) 59 (51.8%) 
0.10 
Male 69 (59.0%) 48 (41.0%) 
Congestive Cardiac 
Failure (CCF) 
No 107 (55.4%) 86 (44.6%) 
0.23 
Yes 17 (44.7%) 21 (55.3%) 
Hypertension (HTN) No 48 (59.3%) 33 (40.7%) 
0.21 
Yes 76 (50.7%) 74 (49.3%) 
Diabetes mellitus (DM) No 95 (50.3%) 94 (49.7%) 
  0.027 
Yes 29 (69.0%) 13 (31.0%) 
Cerebrovascular 
accident/ transient 
ischaemic attack 
(CVA/TIA) 
No 118 (54.9%) 97 (45.1%) 
0.18 
Yes 6 (37.5%) 10 (62.5%) 
CHADS2 (stroke risk 
score) 
0 - 1 80 (58.8%) 56 (41.2%) 
0.11 2 28 (43.1%) 37 (56.9%) 
3+ 16 (53.3%) 14 (46.7%) 
Dyslipidaemia No 71 (60.2%) 47 (39.8%)   0.043 
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Yes 53 (46.9%) 60 (53.1%) 
Known CAD No 107 (55.2%) 87 (44.8%) 
0.30 
Yes 17 (45.9%) 20 (54.1%) 
Smoking No 63 (51.6%) 59 (48.4%) 
0.51 
Yes 61 (56.0%) 48 (44.0%) 
ST Depression No 103 (60.6%) 67 (39.4%) 
  <0.001 
Yes 21 (34.4%) 40 (65.6%) 
Dyspnea Negative 104 (54.7%) 86 (45.3%) 
0.49 
Positive 20 (48.8%) 21 (51.2%) 
Palpitation Negative 78 (55.3%) 63 (44.7%) 
0.53 
Positive 46 (51.1%) 44 (48.9%) 
Chest pain  Negative 66 (50.4%) 65 (49.6%) 
0.25 
Positive 58 (58.0%) 42 (42.0%) 
Atrial fibrillation (AF) New AF 57 (52.3%) 52 (47.7%) 
0.52 
PAF 48 (52.2%) 44 (47.8%) 
Persistent, long 
standing 
persistent, 
permanent AF 
19 (63.3%) 11 (36.7%) 
Age     63.8 (12.4)   68.7 (12.6)   0.004 
Body Mass Index (BMI)     31.3 (6.7)   29.7 (6.4)   0.078 
Heart Rate     119.4 (30.4)   133.4 (25.4) <0.001 
Ejection Fraction % (EF)     59.2 (11.9)   57.7 (14.4)   0.39 
Haemoglobin (Hb)     142.9 (16.2)   141.5 (16.1)   0.52 
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Creatinine     83.8 (21.3)   87.7 (27.5)   0.23 
Thyroid stimulating 
hormone (TSH) 
    1.9 (1.5)   2.5 (5.4)   0.29 
* EF, Creatinine and TSH checked using Mann-Whitney U test which yielded similar results 
with p=0.77, p=0.43, and p=0.66 respectively. 
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Table 2. Binary logistic regression model for cTnI elevation 
 OR (95% CI) p-value 
Heart rate 1.02 (1.01 – 1.03) 0.002 
Diabetes Mellitus 0.32 (0.14 – 0.73) 0.007 
CHADS2 
2 
3+ 
 
2.20 (1.10 – 4.38) 
2.44 (0.97 – 6.13) 
0.038 
ST depression 2.24 (1.17 – 4.29) 0.015 
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Table 3. Relationship of patient characteristics and clinical variables against sCAD 
Variable Categories No significant 
CAD (n=189) 
Significant 
CAD (n=42) 
p-value 
Gender Female   99 (86.8%)   15 (13.2%) 
 0.051 
Male   90 (76.9%)   27 (23.1%) 
CCF No   162 (83.9%)   31 (16.1%) 
 0.06 
Yes   27 (71.1%)   11 (28.9%) 
HTN No   68 (84.0%)   13 (16.0%) 
 0.54 
Yes   121 (80.7%)   29 (19.3%) 
DM No   156 (82.5%)   33 (17.5%) 
 0.55 
Yes   33 (78.6%)   9 (21.4%) 
CVA/TIA No   175 (81.4%)   40 (18.6%) 
 0.74 
Yes   14 (87.5%)   2 (12.5%) 
CHADS2 score 0 - 1   113 (83.1%)   23 (16.9%) 
 0.19 
2   55 (84.6%)   10 (15.4%) 
3+   21 (70.0%)   9 (30.0%) 
Dyslipidaemia No   95 (80.5%)   23 (19.5%) 
 0.60 
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Yes   94 (83.2%)   19 (16.8%) 
Known CAD No   166 (85.6%)   28 (14.4%) 
 0.001 
Yes   23 (62.2%)   14 (37.8%) 
Smoking No   101 (82.8%)   21 (17.2%) 
 0.69 
Yes   88 (80.7%)   21 (19.3%) 
ST Depression No   143 (84.1%)   27 (15.9%) 
 0.13 
Yes   46 (75.4%)   15 (24.6%) 
Dyspnea No   161 (84.7%)   29 (15.3%) 
 0.013 
Yes   28 (68.3%)   13 (31.7%) 
Palpitation No   107 (75.9%)   34 (24.1%) 
 0.003 
Yes   82 (91.1%)   8 (8.9%) 
Chest pain No   110 (84.0%)   21 (16.0%) 
 0.33 
Yes   79 (79.0%)   21 (21.0%) 
AF New AF   83 (76.1%)   26 (23.9%) 
 0.057 
 
PAF   82 (89.1%)   10 (10.9%) 
Persistent, long 
standing 
persistent, 
permanent AF 
  24 (80.0%)   6 (20.0%) 
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Age 
  65.7 (13.1)  67.5 (10.5) 0.43 
BMI 
  30.8 (6.8)  29.6 (5.8) 0.33 
Heart Rate 
  127.3 (29.3)  119.6 (27.1) 0.12 
Ejection Function % 
(EF) 
  59.8 (12.2)  52.7 (15.5) 0.001 
Haemoglobin (Hb) 
  142.0 (15.9)  143.6 (17.3) 0.57 
Creatinine 
  83.4 (22.6)  95.4 (29.4) 0.004 
TSH 
  1.9 (1.4)  3.5 (8.4) 0.013 
*EF, creatinine and TSH checked using Mann-Whitney U test which yielded similar results 
with p=0.006, p=0.006, and p=0.061 respectively. 
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Table 4. Models of sCAD from troponin 
*Model 1 adjusted for EF, known CAD and palpitations. Model 2 adjusted for heart rate, 
known CAD, ST depression, and dyspnea. 
 
 
Unadjusted Adjusted* 
OR (95% CI) p-value OR (95% CI) p-value 
(Model 1) 
cTnI > 0.04 
1.70 (0.87 – 3.35) 0.12 1.62 (0.79 – 3.23) 0.19 
(Model 2) 
cTnI peak 
2.01 (1.10 – 3.69) 0.024 2.02 (1.02 – 3.97) 0.042 
